Eisai’s Ontak sBLA Granted U.S. FDA Approval
This article was originally published in PharmAsia News
TOKYO - U.S. FDA granted full approval to Eisai's biologic Ontak (denileukin) for intravenous injection for treating a recurrent type of lymph node cancer, cutaneous T-cell lymphoma in patients whose malignant cells express the CD25 component of the interleukin-2 receptor
You may also be interested in...
TOKYO - Eisai has signed a licensing agreement with Japanese start-up SymBio Pharmaceuticals to jointly develop and commercialize lymphoma treatment bendamustine (SyB L-0501) in Japan
Case Study: Eisai Partners With Swedish Startup BioArctic In Search Of Cure For Alzheimer’s Disease (Part 2 Of 2)
Eisai has taken an aggressive approach in seeking out the right partners to fill out its pipelines. The company's partnership with Swedish startup BioArctic to develop a drug for Alzheimer's disease is no exception. Eisai and BioArctic discussed the beginnings of their partnership in the first part of this case study (PharmAsia News, Aug. 6, 2008). This second section discusses in greater detail why the companies view the partnership as a success and what each has brought to the other.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).